N/A
N=306
Implementing Prescriber-Pharmacist Collaborative Care for Evidence-based Anticoagulant Use
Pulmonary Embolism · Venous Thromboembolism · Atrial Fibrillation
Bottom Line
View on ClinicalTrials.gov: NCT05351749 ↗Enrolled (actual)
306
Serious AEs
—
Results posted
Mar 2026
Primary outcome: Primary: The Number (Proportion) of Notifications (in the Existing-prescription Notification Conditions) That Are Addressed Within 7 Days. — 24.86; 21.74 percent of notifications
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- New-prescription Alert (Behavioral); New-prescription Alert with referral option (Behavioral); Existing-prescription notification to prescriber (Behavioral); Existing-prescription notification to pharmacist (Behavioral)
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- University of Michigan
- Primary completion
- Dec 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY The Number (Proportion) of Notifications (in the Existing-prescription Notification Conditions) That Are Addressed Within 7 Days. |
24.86; 21.74 | — |
| SECONDARY The Number (Proportion) of Alerts (in the Newly Prescribed DOAC Alert Conditions) That Are Addressed Within 7 Days. |
29.84; 29.10 | — |
| SECONDARY Change in Effect Size for the Existing-prescription Notification Over Time |
17.58; 27.95; 25.81 | — |
| SECONDARY Change in Effect Size for the Initial Alert Over Time |
30.06; 28.47; 29.63 | — |
Summary
The researchers hypothesize that existing-prescription notifications directed to pharmacists are more likely to lead to a prescription change than existing-prescription notifications directed to prescribers. Furthermore, the researchers hypothesize that the availability of a pharmacist referral option is associated with a higher rate of prescription changes for initial-prescription alerts that are directed to the prescriber at the time of initial-prescribing errors.
Findings from this project will establish a framework for implementing prescriber-pharmacist collaboration for high risk medications, including anticoagulants
Eligibility Criteria
Prescribers:
Inclusion Criteria
- Michigan Medicine provider with prescribing privileges
- Providers in ambulatory care settings
- Prescribe DOAC to patients 18 years and older
Exclusion Criteria
- Providers in inpatient settings
- Providers who are members of the study team
Data sourced from ClinicalTrials.gov (NCT05351749). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.